EDIT at a glance
Editas Medicine, Inc. (EDIT, SEC CIK 1650664) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Editas Medicine, Inc. (EDIT) reported revenue of $40.5 million (up 25.4% from FY2024) and a net loss of $160.1 million. Diluted EPS was -$1.80.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Editas Medicine, Inc. (EDIT) shares worth $132.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by O'Neill Gilmore Neil on November 11, 2026 of 21,164 shares at $2.42 per share.
- In the last 90 days, EDIT insiders reported 0 open-market purchases ($0) and 5 open-market sales ($89K) on Form 4, a net sale of $89K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $40.5M
- +25.4% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$89K
- 13F holders
- 28 funds
- $132.3M · +2 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $10.4M, up $2.8M from $7.5M YoY, driven by strategic-partner clinical milestones
- Net loss $23.4M vs $25.1M YoY, with operating expenses $34.6M vs $32.1M
- Research and development $21.2M, up $1.4M YoY, driven by $3.6M higher sublicense and license fees
- Cash, equivalents, and marketable securities $190.2M; operating cash outflow $73.8M through nine months
- EDIT-401 dosing on track for 2026; initial safety data expected first quarter 2027, cash runway into second half of 2028
Risk Factors
- No updated Risk Factors text provided, so no newly added quarterly risk identified
- Liquidity risk: accumulated deficit $1.7 billion and substantial additional capital required despite $190.2 million in cash, equivalents, and marketable securities
- Regulatory and legal risk: Cas9-I patent license disputes require $10.8 million reimbursement payments year-to-date
- Operational risk: gene-editing programs depend on successful clinical development, regulatory approval, manufacturing, and commercialization
- Financial risk: DRI revenue-sale liability $56.8 million, with estimated effective interest rate 7.7%
AI summary of the EDIT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Editas Medicine reported financial results for the quarter ended September 30, 2026
- Business highlights accompany the quarterly results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Phase 1/2 Strive study approved in Australia, with EDIT-401 dosing expected in 2026 and initial safety data targeted for Q1 2027
- EDIT-401 preclinical LDL-C reduction of ≥90% maintained over 10 months, supporting potential durability but not yet demonstrating human efficacy
Item 8.01: Other Events
- Australia approval enables Phase 1/2 Strive trial of EDIT-401 in heterozygous familial hypercholesterolemia
- EDIT-401 targets LDLR upregulation, with approximately 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates
Item 7.01: Regulation FD Disclosure
- FDA approval to initiate first-in-human EDIT-401 trial in hyperlipidemia
- Clinical-stage milestone enabling initial human safety and efficacy testing
Item 2.02: Results of Operations and Financial Condition
- Press release covers Editas Medicine’s quarter ended June 30, 2026 financial results
- Exhibit 99.1 contains business highlights and detailed quarterly results
Item EX-99.1: Item EX-99.1
- EDIT-401 CTN submission targeted for August 2026, with Phase 1/2 data update expected in Q1 2027
- Preclinical EDIT-401 data showed approximately 90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Elliott Levy resigned as class I director effective August 4, 2026, without disagreement with Editas Medicine
- Patrick Ellinor appointed independent class I director effective August 6, 2026
AI summaries of EDIT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for EDIT
Don't miss the next EDIT filing
- Alerts as it files. A push when EDIT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut EDIT, by share count.
- Ask anything. An AI agent that reads every EDIT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| O'Neill Gilmore Neil | Sell | Nov 11, 2026 | 21,164 | $2.42 |
| Burkly Linda | Sell | Nov 11, 2026 | 7,814 | $2.42 |
| Burkly Linda | A | Nov 5, 2026 | 16,533 | - |
| O'Neill Gilmore Neil | A | Nov 5, 2026 | 43,567 | - |
| Ory Daniel Scott | A | Sep 8, 2026 | 950,000 | - |
| Parison Amy | Sell | Sep 3, 2026 | 453 | $3.04 |
| Burkly Linda | Sell | Sep 3, 2026 | 709 | $3.04 |
| O'Neill Gilmore Neil | Sell | Sep 3, 2026 | 5,124 | $3.04 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $32.3M | $40.5M |
| Operating Income | - | -$251.2M | -$160.0M |
| Net Income | -$153.2M | -$237.1M | -$160.1M |
| Op. Margin | - | -777.2% | -394.9% |
| Net Margin | - | -733.7% | -395.0% |
| Balance Sheet | |||
| Total Assets | $499.2M | $341.6M | $186.5M |
| Equity | - | $134.3M | $27.3M |
| ROE | - | -176.6% | -586.6% |
| Per Share | |||
| EPS | $-2.02 | $-2.88 | $-1.80 |
| Cash Flow | |||
| Operating CF | - | -$210.3M | -$165.2M |
| CapEx | $4.7M | $8.8M | $607K |
Source: XBRL data in Editas Medicine, Inc. (EDIT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate EDIT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $132.3M |
| Q2 2026 | 26 | $125.1M |
| Q1 2026 | 26 | $84.2M |
| Q4 2025 | 26 | $67.0M |
| Q3 2025 | 26 | $98.1M |
| Q2 2025 | 26 | $62.5M |
| Q1 2025 | 23 | $26.0M |
| Q4 2024 | 20 | $26.9M |
- State Street Corp+4.85M (+221%)
- BlackRock+3.81M (+36%)
- D.E. Shaw & Co+1.29M (+68%)
- Vanguard Portfolio Management LLC+1.08M (+30%)
- Goldman Sachs Group+631.0K (+24%)
- AQR Capital Management−590.7K (-38%)
- Millennium Management−287.5K (-58%)
- Vanguard Capital Management LLC−67.9K (-1%)
- Wells Fargo & Co−47.4K (-39%)
- Two Sigma Investments−12.8K (-1%)
- Ameriprise Financial+1.13M
- Principal Financial Group+32.9K
- U.S. Bancorp+91
- FMR LLC (Fidelity)−111.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
EDIT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 8-K | Oct 8, 2026 | - | Analysis | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 29, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
EDIT SEC filings: frequently asked questions
Are EDIT insiders buying or selling?
In the last 90 days, Editas Medicine, Inc. (EDIT) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $89,088 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold EDIT stock?
As of September 30, 2026, the largest Editas Medicine, Inc. (EDIT) holders among the 13F filers tracked by SignalX were BlackRock ($37.0 million), State Street Corp ($18.1 million), Vanguard Capital Management LLC ($15.6 million), Vanguard Portfolio Management LLC ($12.0 million), Goldman Sachs Group ($8.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was EDIT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Editas Medicine, Inc. (EDIT) reported revenue of $40.5 million (up 25.4% from FY2024) and a net loss of $160.1 million. Diluted EPS was -$1.80. The figures come from the XBRL data in the 10-K.
What did EDIT report in its latest 8-K?
Editas Medicine, Inc. (EDIT) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Editas Medicine reported financial results for the quarter ended September 30, 2026.
What are the latest EDIT SEC filings?
Editas Medicine, Inc. (EDIT) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 13, 2026.
What is EDIT's SEC CIK number?
Editas Medicine, Inc. (EDIT)'s SEC Central Index Key (CIK) is 1650664. EDGAR lists every EDIT filing under that number.
Ask anything about EDIT
The research agent reads EDIT's filings, financials, insider trades and 13F holders, then answers with sources.